Search

Your search keyword '"Caldwell, Stephen H."' showing total 800 results
Start Over Author "Caldwell, Stephen H."
800 results on '"Caldwell, Stephen H."'

2. Expert opinion on bleeding risk from invasive procedures in cirrhosis

Author

Nezam H, Afdhal, Walter, Ageno, Marcello, Bianchini, Annabel, Blasi, Stephen H, Caldwell, Mark, Callaway, Andres, Cardenas, Sarwa, Darwish Murad, Andrea, De Gottardi, Lesley, De Pietri, Emmanuelle, De Raucourt, Alessandra, Dell'Era, Alban, Denys, Laure, Elkrief, Juan-Carlos, Garcia-Pagan, Guadalupe, Garcia-Tsao, Alexander, Gatt, Edoardo G, Giannini, Rita, Golfieri, Charles S, Greenberg, Virginia, Hernández-Gea, Mathis, Heydtmann, Nicolas M, Intagliata, Patrick S, Kamath, Will, Lester, Maria, Magnusson, James, Neuberger, Patrick G, Northup, G, O'Leary Jacqueline, Heather, Patton, Markus, Peck-Radosavljevic, Anjana, Pillai, Aurélie, Plessier, Pierre-Emmanuel, Rautou, Cristina, Ripoll, Lara N, Roberts, Ammar, Sarwar, Marco, Senzolo, Akash, Shukla, Paolo, Simioni, Douglas A, Simonetto, Ashwani K, Singal, Robin, Soto, Jonathan G, Stine, Elliot B, Tapper, Dominique, Thabut, Jecko, Thachil, Dana, Tomescu, Dhiraj, Tripathi, Emmanuel A, Tsochatzis, Erica, Villa, Dominique, Valla, Riescher-Tuczkiewicz, Alix, Caldwell, Stephen H., Kamath, Patrick S., Villa, Erica, and Rautou, Pierre-Emmanuel

Published
2024
Full Text
View/download PDF

4. Expert opinion on bleeding risk from invasive procedures in cirrhosis

Author

Alix Riescher-Tuczkiewicz, Stephen H. Caldwell, Patrick S. Kamath, Erica Villa, Pierre-Emmanuel Rautou, Afdhal Nezam H, Ageno Walter, Bianchini Marcello, Blasi Annabel, Caldwell Stephen H, Callaway Mark, Cardenas Andres, Darwish Murad Sarwa, De Gottardi Andrea, De Pietri Lesley, De Raucourt Emmanuelle, Dell'Era Alessandra, Denys Alban, Elkrief Laure, Garcia-Pagan Juan-Carlos, Garcia-Tsao Guadalupe, Gatt Alexander, Giannini Edoardo G, Golfieri Rita, Greenberg Charles S, Hernández-Gea Virginia, Heydtmann Mathis, Intagliata Nicolas M, Kamath Patrick S, Lester Will, Magnusson Maria, Neuberger James, Northup Patrick G, O'Leary Jacqueline G, Patton Heather, Peck-Radosavljevic Markus, Pillai Anjana, Plessier Aurélie, Rautou Pierre-Emmanuel, Ripoll Cristina, Roberts Lara N, Sarwar Ammar, Senzolo Marco, Shukla Akash, Simioni Paolo, Simonetto Douglas A, Singal Ashwani K, Soto Robin, Stine Jonathan G, Tapper Elliot B, Thabut Dominique, Thachil Jecko, Tomescu Dana, Tripathi Dhiraj, Tsochatzis Emmanuel A, Villa Erica, and Valla Dominique

Subjects
haemorrhage, coagulation, haemostasis, biopsy, anticoagulant, procedural related bleeding, Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

Background & Aims: Despite several recent international guidelines, no consensus exists on the bleeding risk nor haemostatic parameter thresholds that define the safety of invasive procedures in patients with cirrhosis. The aim of this study was to establish a position paper on the bleeding risk associated with invasive procedures in patients with cirrhosis among the experts involved in various guidelines. Methods: All experts involved in recent guidelines on the management of invasive procedures in patients with cirrhosis were invited to classify 80 procedures as ''high risk'' or ''low risk'' with respect to bleeding. Procedures were considered high risk when the estimated risk of major bleeding was 1.5% or more, or when even minor bleeding might lead to significant morbidity or death. The experts were also asked to choose safety thresholds for laboratory test values at which elective invasive procedures could be safely performed. The predetermined threshold considered as “consensus” was ≥75% agreement. Results: Fifty-two experts participated in the study. Out of 80 procedures, a consensus opinion was reached for 52 procedures (65%): 17 procedures were classified as “high risk”, primarily interventional endoscopic procedures, percutaneous organ biopsies, or procedures involving the central nervous system; and 35 as “low risk”, primarily “diagnostic” procedures. The lowest platelet counts at which performance of a low-risk procedure or a high-risk procedure/surgery were deemed acceptable were 30 × 109/L and 50 × 109/L, respectively. Experts did not believe that international normalised ratio should be considered before performing low-risk procedures; 71% also indicated that it should not be considered before performing high-risk procedures. Conclusions: This experience-based classification may be helpful to refine future study designs and to guide clinical decision making regarding invasive procedures in patients with cirrhosis. Impact and implications: Several risk classifications and management guidelines for invasive procedures in patients with cirrhosis have been proposed, but with conflicting recommendations. By providing a position paper, based on the opinion of a broad panel of experts, on the bleeding risk associated with 52 invasive procedures in patients with cirrhosis, this survey will help to provide a framework for future study design. The consensus on platelet count, international normalised ratio, fibrinogen and activated partial thromboplastin time identified in this survey will inform physicians regarding the laboratory test values considered acceptable by the experts prior to the performance of an elective invasive procedure in patients with cirrhosis.

Published
2024
Full Text
View/download PDF

5. Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient‐Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis

Author

Younossi, Zobair M, Stepanova, Maria, Noureddin, Mazen, Kowdley, Kris V, Strasser, Simone I, Kohli, Anita, Ruane, Peter, Shiffman, Mitchell L, Sheikh, Aasim, Gunn, Nadege, Caldwell, Stephen H, Huss, Ryan S, Myers, Robert P, Wong, Vincent Wai‐Sun, Alkhouri, Naim, Goodman, Zachary, and Loomba, Rohit

Subjects
Clinical Research, Digestive Diseases, Hepatitis, Chronic Liver Disease and Cirrhosis, Liver Disease, Clinical Trials and Supportive Activities, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Oral and gastrointestinal, Good Health and Well Being
Abstract

Patient-reported outcomes (PROs) are important endpoints for clinical trials. The impact of investigational drugs on PROs of patients with advanced nonalcoholic steatohepatitis (NASH) was investigated. Patients with NASH with bridging fibrosis or compensated cirrhosis were enrolled in a phase 2, randomized, placebo-controlled study of selonsertib, firsocostat, or cilofexor, alone or in two-drug combinations (NCT03449446). PROs included Short Form 36 (SF-36), Chronic Liver Disease Questionnaire (CLDQ)-NASH, EuroQol Five Dimension (EQ-5D), Work Productivity and Impairment (WPAI), and 5-D Itch before and during treatment. A total of 392 patients with NASH (mean ± SD, 60 ± 9 years old; 35% men; 89% white; 72% diabetes; and 56% compensated cirrhosis) were included. Baseline Physical Functioning (PF) and Bodily Pain of SF-36 and Fatigue and Worry of CLDQ-NASH were significantly lower in patients with cirrhosis (total CLDQ-NASH score mean ± SD, 4.91 ± 1.06 with cirrhosis vs. 5.16 ± 1.14 without cirrhosis; P

Published
2021

6. Procedural-Related Bleeding in Hospitalized Patients With Liver Disease (PROC-BLeeD): An International, Prospective, Multicenter Observational Study

Author

Intagliata, Nicolas M., Rahimi, Robert S., Higuera-de-la-Tijera, Fatima, Simonetto, Douglas A., Farias, Alberto Queiroz, Mazo, Daniel F., Boike, Justin R., Stine, Jonathan G., Serper, Marina, Pereira, Gustavo, Mattos, Angelo Z., Marciano, Sebastian, Davis, Jessica P.E., Benitez, Carlos, Chadha, Ryan, Méndez-Sánchez, Nahum, deLemos, Andrew S., Mohanty, Arpan, Dirchwolf, Melisa, Fortune, Brett E., Northup, Patrick G., Patrie, James T., and Caldwell, Stephen H.

Published
2023
Full Text
View/download PDF

10. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib

Author

Jayakumar, Saumya, Middleton, Michael S, Lawitz, Eric J, Mantry, Parvez S, Caldwell, Stephen H, Arnold, Hays, Diehl, Anna Mae, Ghalib, Reem, Elkhashab, Magdy, Abdelmalek, Manal F, Kowdley, Kris V, Djedjos, C Stephen, Xu, Ren, Han, Ling, Subramanian, G Mani, Myers, Robert P, Goodman, Zachary D, Afdhal, Nezam H, Charlton, Michael R, Sirlin, Claude B, and Loomba, Rohit

Subjects
Digestive Diseases, Hepatitis, Substance Misuse, Clinical Research, Chronic Liver Disease and Cirrhosis, Liver Disease, Biomedical Imaging, 4.2 Evaluation of markers and technologies, 4.1 Discovery and preclinical testing of markers and technologies, Detection, screening and diagnosis, Oral and gastrointestinal, Good Health and Well Being, Adolescent, Adult, Aged, Benzamides, Biopsy, Disease Progression, Dose-Response Relationship, Drug, Elasticity Imaging Techniques, Female, Humans, Imidazoles, Injections, Subcutaneous, Liver, Magnetic Resonance Imaging, Male, Middle Aged, Non-alcoholic Fatty Liver Disease, Pyridines, ROC Curve, Reproducibility of Results, Treatment Outcome, Young Adult, Non-alcoholic fatty liver disease, Non-alcoholic steatohepatitis, Hepatic steatosis, Non-invasive tests, Liver biopsy, Clinical Sciences, Public Health and Health Services, Gastroenterology & Hepatology
Abstract

Background & aimsNon-invasive tools for monitoring treatment response and disease progression in non-alcoholic steatohepatitis (NASH) are needed. Our objective was to evaluate the utility of magnetic resonance (MR)-based hepatic imaging measures for the assessment of liver histology in patients with NASH.MethodsWe analyzed data from patients with NASH and stage 2 or 3 fibrosis enrolled in a phase II study of selonsertib. Pre- and post-treatment assessments included centrally read MR elastography (MRE)-estimated liver stiffness, MR imaging-estimated proton density fat fraction (MRI-PDFF), and liver biopsies evaluated according to the NASH Clinical Research Network classification and the non-alcoholic fatty liver disease activity score (NAS).ResultsAmong 54 patients with MRE and biopsies at baseline and week 24, 18 (33%) had fibrosis improvement (≥1-stage reduction) after undergoing 24 weeks of treatment with the study drug. The area under the receiver operating characteristic curve (AUROC) of MRE-stiffness to predict fibrosis improvement was 0.62 (95% CI 0.46-0.78) and the optimal threshold was a ≥0% relative reduction. At this threshold, MRE had 67% sensitivity, 64% specificity, 48% positive predictive value, 79% negative predictive value. Among 65 patients with MRI-PDFF and biopsies at baseline and week 24, a ≥1-grade reduction in steatosis was observed in 18 (28%). The AUROC of MRI-PDFF to predict steatosis response was 0.70 (95% CI 0.57-0.83) and the optimal threshold was a ≥0% relative reduction. At this threshold, MRI-PDFF had 89% sensitivity and 47% specificity, 39% positive predictive value, and 92% negative predictive value.ConclusionsThese preliminary data support the further evaluation of MRE-stiffness and MRI-PDFF for the longitudinal assessment of histologic response in patients with NASH.Lay summaryLiver biopsy is a potentially painful and risky method to assess damage to the liver due to non-alcoholic steatohepatitis (NASH). We analyzed data from a clinical trial to determine if 2 methods of magnetic resonance imaging - 1 to measure liver fat and 1 to measure liver fibrosis (scarring) - could potentially replace liver biopsy in evaluating NASH-related liver injury. Both imaging methods were correlated with biopsy in showing the effects of NASH on the liver.

Published
2019

13. Systematic review with meta‐analysis: risk of hepatocellular carcinoma in non‐alcoholic steatohepatitis without cirrhosis compared to other liver diseases

Author

Stine, Jonathan G, Wentworth, Brian J, Zimmet, Alex, Rinella, Mary E, Loomba, Rohit, Caldwell, Stephen H, and Argo, Curtis K

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Chronic Liver Disease and Cirrhosis, Hepatitis, Liver Disease, Liver Cancer, Prevention, Cancer, Clinical Research, Rare Diseases, Digestive Diseases, Oral and gastrointestinal, Good Health and Well Being, Carcinoma, Hepatocellular, Case-Control Studies, Cohort Studies, Humans, Liver Cirrhosis, Liver Diseases, Liver Neoplasms, Non-alcoholic Fatty Liver Disease, Observational Studies as Topic, Prospective Studies, Risk Factors, Pharmacology and Pharmaceutical Sciences, Gastroenterology & Hepatology, Clinical sciences, Pharmacology and pharmaceutical sciences
Abstract

BACKGROUND:Given the lack of long-term prospective studies, it is challenging for clinicians to make informed decisions about screening and treatment decisions regarding the risk of hepatocellular carcinoma (HCC) in patients with non-alcoholic steatohepatitis (NASH) who do not have cirrhosis. AIM:To characterise the pooled risk of HCC in the non-cirrhosis population. METHODS:Published studies were identified through April 2016 in MEDLINE, Scopus, Science Citation Index, AMED and the Cochrane Library. Two independent reviewers screened citations and extracted data. Random effect odds ratios (OR) were calculated to obtain aggregate estimates of effect size between NASH and non-NASH groups. Between-study variability and heterogeneity were assessed. RESULTS:Nineteen studies with 168 571 participants were included. Eighty-six per cent of included subjects had cirrhosis. The prevalence of HCC in non-cirrhotic NASH was 38.0%; among other aetiologies in non-cirrhotics, it was 14.2% (P

Published
2018

14. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis

Author

Younossi, Zobair M, Loomba, Rohit, Anstee, Quentin M, Rinella, Mary E, Bugianesi, Elisabetta, Marchesini, Giulio, Neuschwander‐Tetri, Brent A, Serfaty, Lawrence, Negro, Francesco, Caldwell, Stephen H, Ratziu, Vlad, Corey, Kathleen E, Friedman, Scott L, Abdelmalek, Manal F, Harrison, Stephen A, Sanyal, Arun J, Lavine, Joel E, Mathurin, Philippe, Charlton, Michael R, Goodman, Zachary D, Chalasani, Naga P, Kowdley, Kris V, George, Jacob, and Lindor, Keith

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Liver Disease, Chronic Liver Disease and Cirrhosis, Digestive Diseases, Clinical Research, Hepatitis, Oral and gastrointestinal, Good Health and Well Being, Biomarkers, Collagen, Humans, Liver, Liver Cirrhosis, Non-alcoholic Fatty Liver Disease, Medical Biochemistry and Metabolomics, Immunology, Gastroenterology & Hepatology, Clinical sciences
Abstract

Nonalcoholic fatty liver disease (NAFLD) is a spectrum comprised of isolated steatosis, nonalcoholic steatohepatitis (NASH), advanced fibrosis, and cirrhosis. The majority of NAFLD subjects do not have NASH and do not carry a significant risk for liver-related adverse outcomes (cirrhosis and mortality). Globally, the prevalence of NAFLD is approximately 25%. In Asia, a gradient of high to low prevalence rates is noted from urban to rural areas. Given the prevalence of NAFLD, the clinical and economic burden of NAFLD and NASH can be substantial. With increasing recognition of NASH as an important liver disease, the diagnosis of NASH still requires a liver biopsy that is suboptimal. Although liver biopsy is the most accurate modality to diagnose and stage the severity of NASH, this method suffers from being invasive, costly, associated with potential complications, and plagued with interobserver variability of individual pathological features. A number of noninvasive modalities to diagnose NASH and stage liver fibrosis are being developed. These modalities include predictive models (NAFLD fibrosis score) and serum biomarkers such as enhanced liver fibrosis (ELF). Other tests are based on radiological techniques, such as transient elastography (TE) or magnetic resonance elastography (MRE), which are used to estimate liver stiffness as a potential surrogate of hepatic fibrosis. Although a dynamic field of research, most of these diagnostic modalities have area under the curve ranging between 0.76 and 0.90%, with MRE having the best predictive performance. In summary, developing safe and easily accessible noninvasive modalities to accurately diagnose and monitor NASH and associated fibrosis is of utmost importance in clinical practice and clinical research. These tests are not only important to risk stratify subjects at the greatest risk for progressive liver disease, but also to serve as appropriate surrogate endpoints for therapeutic clinical trials of NASH. (Hepatology 2018;68:349-360).

Published
2018

15. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

Author

Younossi, Zobair M, Loomba, Rohit, Rinella, Mary E, Bugianesi, Elisabetta, Marchesini, Giulio, Neuschwander‐Tetri, Brent A, Serfaty, Lawrence, Negro, Francesco, Caldwell, Stephen H, Ratziu, Vlad, Corey, Kathleen E, Friedman, Scott L, Abdelmalek, Manal F, Harrison, Stephen A, Sanyal, Arun J, Lavine, Joel E, Mathurin, Philippe, Charlton, Michael R, Chalasani, Naga P, Anstee, Quentin M, Kowdley, Kris V, George, Jacob, Goodman, Zachary D, and Lindor, Keith

Subjects
Hepatitis, Liver Disease, Chronic Liver Disease and Cirrhosis, Prevention, Clinical Trials and Supportive Activities, Clinical Research, Digestive Diseases, Rare Diseases, Oral and gastrointestinal, Good Health and Well Being, Clinical Trials as Topic, Exercise, Humans, Liver Transplantation, Non-alcoholic Fatty Liver Disease, Obesity, Weight Loss, Medical Biochemistry and Metabolomics, Clinical Sciences, Immunology, Gastroenterology & Hepatology
Abstract

Nonalcoholic fatty liver disease (NAFLD) and its progressive form non-alcoholic steatohepatitis (NASH), are rapidly becoming among the top causes of cirrhosis, hepatocellular carcinoma, and indications for liver transplantation. Other than lifestyle modification through diet and exercise, there are currently no other approved treatments for NASH/NAFLD. Although weight loss can be effective, it is difficult to achieve and sustain. In contrast, bariatric surgery can improve metabolic conditions associated with NAFLD, and has been shown to improve liver histology. To have approved regimens for the treatment of NASH/NAFLD, several issues must be addressed. First, all stakeholders must agree on the most appropriate clinical trial endpoints for NASH. Currently, resolution of NASH (without worsening fibrosis) or reduction of fibrosis stage (without worsening NASH) are the accepted endpoints by the regulatory authorities. It is important to recognize the prognostic implication of histologic features of NASH. In this context, although histologic NASH has been associated with advanced fibrosis, it is not an independent predictor of long-term mortality. In contrast, there are significant data to suggest that fibrosis stage is the only robust and independent predictor of liver-related mortality. In addition to the primary endpoints, several important secondary endpoints, including noninvasive biomarkers, long-term outcomes, and patient-reported outcomes must be considered. In 2018, a few phase 3 clinical trials for the treatment of NASH have been initiated. Additionally, a number of phase 2a and 2b clinical trials targeting different pathogenic pathways in NASH are in the pipeline of emerging therapies.ConclusionOver the next 5 years, some of these regimens are expected to provide potential new treatment options for patients with NASH/NAFLD. (Hepatology 2018;68:361-371).

Published
2018

16. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial

Author

Loomba, Rohit, Lawitz, Eric, Mantry, Parvez S, Jayakumar, Saumya, Caldwell, Stephen H, Arnold, Hays, Diehl, Anna Mae, Djedjos, C Stephen, Han, Ling, Myers, Robert P, Subramanian, G Mani, McHutchison, John G, Goodman, Zachary D, Afdhal, Nezam H, Charlton, Michael R, and Investigators, for the GS‐US‐384‐1497

Subjects
Clinical Trials and Supportive Activities, Digestive Diseases, Chronic Liver Disease and Cirrhosis, Liver Disease, Hepatitis, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Oral and gastrointestinal, Antibodies, Monoclonal, Humanized, Benzamides, Elasticity Imaging Techniques, Female, Humans, Imidazoles, Liver Cirrhosis, MAP Kinase Kinase Kinase 5, Male, Middle Aged, Non-alcoholic Fatty Liver Disease, Protein Kinase Inhibitors, Pyridines, GS-US-384-1497 Investigators, Medical Biochemistry and Metabolomics, Clinical Sciences, Immunology, Gastroenterology & Hepatology
Abstract

Inhibition of apoptosis signal-regulating kinase 1, a serine/threonine kinase, leads to improvement in inflammation and fibrosis in animal models of nonalcoholic steatohepatitis. We evaluated the safety and efficacy of selonsertib, a selective inhibitor of apoptosis signal-regulating kinase 1, alone or in combination with simtuzumab, in patients with nonalcoholic steatohepatitis and stage 2 or 3 liver fibrosis. In this multicenter phase 2 trial, 72 patients were randomized to receive 24 weeks of open-label treatment with either 6 or 18 mg of selonsertib orally once daily with or without once-weekly injections of 125 mg of simtuzumab or simtuzumab alone. The effect of treatment was assessed by paired pretreatment and posttreatment liver biopsies, magnetic resonance elastography, magnetic resonance imaging-estimated proton density fat fraction, quantitative collagen content, and noninvasive markers of liver injury. Due to the lack of effect of simtuzumab on histology or selonsertib pharmacokinetics, selonsertib groups with and without simtuzumab were pooled. After 24 weeks of treatment, the proportion of patients with a one or more stage reduction in fibrosis in the 18-mg selonsertib group was 13 of 30 (43%; 95% confidence interval, 26-63); in the 6-mg selonsertib group, 8 of 27 (30%; 95% confidence interval, 14-50); and in the simtuzumab-alone group, 2 of 10 (20%; 95% confidence interval, 3-56). Improvement in fibrosis was associated with reductions in liver stiffness on magnetic resonance elastography, collagen content and lobular inflammation on liver biopsy, as well as improvements in serum biomarkers of apoptosis and necrosis. There were no significant differences in adverse events between the treatment groups. Conclusion: These findings suggest that selonsertib may reduce liver fibrosis in patients with nonalcoholic steatohepatitis and stage 2-3 fibrosis. (Hepatology 2018;67:549-559).

Published
2018

19. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Author

Gadano, Adrian, Martins, Marcelo, Angus, Peter, Bate, John, Danta, Mark, George, Jacob, Hodge, Alexander, Kontorinis, Nickolas, Roberts, Stuart, Sanagapalli, Santosh, Skoien, Richard, Thompson, Alexander, Zekry, Amany, Stauber, Rudolf, Trauner, Michael, Moreno, Christophe, Reynaert, Hendrik, Verbeke, Len, Silva, Mario Reis Alvares da, Parise, Edison, Oliveira, Claudia Pinto Marques Souza de, Araujo, Roberta Chaves, Martinelli, Ana de Lourdes Candolo, Borman, Meredith, Chandok, Natasha, Elkhashab, Magdy, Fraser, Hughie, Kaita, Kelly, Ma, Mang, Marotta, Paul, Ramji, Alnoor, Tam, Edward, Yoshida, Eric, Swain, Mark, Sebastiani, Giada, Petrunia, Denis, Abergel, Armando, Anty, Rodolphe, Bourlière, Marc, Boursier, Jérôme, Bureau, Christophe, Castera, Laurent, Habersetzer, François, Hézode, Christophe, Ledinghen, Victor De, Leroy, Vincent, Loustaud-Ratti, Véronique, Mathurin, Philippe, Pol, Stanislas, Zoulim, Fabien, Hinrichsen, Holger, Ingiliz, Patrick, Lammert, Frank, Manns, Michael, Schattenberg, Jörn, Schiefke, Ingolf, Trautwein, Christian, Zeuzem, Stefan, Hui, Aric, Li, King-Kong, Wong, Vincent, Acharya, Subrat, Chowdhury, Abhijit, Duseja, Ajay, Kapoor, Dharmesh, Mukewar, Shrikant, Sarin, Shiv, Shah, Samir, Shalimar, Sood, Ajit, Tantry, BV, Ben-Ari, Ziv, Katchman, Helena, Safadi, Rifaat, Veitsman, Ella, Zuckerman, Eli, Brunetto, Maurizia, Lampertico, Pietro, Mangia, Alessandra, Akahane, Takemi, Akuta, Norio, Eguchi, Yuichiro, Fujiyama, Shigetoshi, Genda, Takuya, Hiasa, Yoichi, Ido, Akio, Ikeda, Fusao, Ikegami, Tadashi, Imajo, Kento, Itoh, Yoshito, Iwasa, Motoh, Karino, Yoshiyasu, Kato, Naoya, Kawaguchi, Takumi, Kawanaka, Miwa, Kido, Masahiro, Kobayashi, Tomoo, Kurosaki, Masayuki, Matsuzaki, Yasushi, Mita, Eiji, Mizukoshi, Eishiro, Nakahara, Takashi, Nomura, Hideyuki, Notsumata, Kazuo, Okanoue, Takeshi, Saito, Satoshi, Sakugawa, Hiroshi, Suzuki, Yoshiyuki, Takaguchi, Koichi, Takaki, Akinobu, Takashima, Tomoyuki, Tanaka, Saiyu, Tsuji, Keiji, Ueno, Yoshiyuki, Umemura, Takeji, Uto, Hirofumi, Yamashita, Nobuyuki, Yanase, Mikio, Yatsuhashi, Hiroshi, Yoneda, Masashi, Chan, Wah Kheong, Tan, Soek Siam, Garza, Laura Cisneros, Ladron De Guevara Cetina, Alma, Angeles, Rocio Guadalupe Vargas, Silva, Francisca Martinez, Van Erpecum, Karel, Orr, David, Jabłkowski, Maciej, Jaroszewicz, Jerzy, Ramos, Jose, Ahmed, Taufique, Ang, Tiing, Dan, Yock young, Goh, Boon Bee, Kaliyaperumal, Kalaiyarasi, Yip, Cherng Hann, Baik, Soon Koo, Jang, Byoung Kuk, Jun, Dae Won, Kim, Won, Kim, Hyung Joon, Kim, Ji Hoon, Lee, Kwan Sik, Lee, Chun Kyon, Lim, Young-Suk, Park, Jun Yong, Tak, Won Young, Augustin, Salvador, Perez, Salvador Benlloch, Caballeria, Juan, Luis, Jose, Panero, Calleja, Rodríguez, Jose Carrión, Garcia, Javier Crespo, Samaniego, Javier Garcia, Gibert, Pere Ginès, Prieto, Martin, Gomez, Manuel Romero, Turnes, Juan, Dufour, Jean-Francois, Moriggia, Alberto, Sheen, I-Shyan, Kao, Jia-Horng, Cheng, Pin-Nan, Huang, Jee-Fu, Yang, Sheng-Shun, Su, Wei-Wen, Chen, Chi-Yi, Chien, Rong-Nan, Lo, Gin-Ho, Chu, Chi-Jen, Wang, Horng-Yuan, Hu, Jui-Ting, Huang, Yi Wen, Agarwal, Kosh, Allison, Michael, Anstee, Quentin, Austin, Andrew, Fowell, Andrew, Ch'ng, Chin Lye, Manousou, Pinelopi, Newsome, Philip, Ryder, Stephen, Shankar, Arun, Abdelmalek, Manal, Abrams, Gary, Aguilar, Humberto, Alam, Imtiaz, Alba, Laura, Alkhouri, Naim, Allen, Alina, Aqel, Bashar, Balart, Luis, Barritt, A. Sidney, IV, Behari, Jaideep, Bennett, Michael, Bernstein, David, Bhandari, Bal Raj, Bonacini, Maurizio, Borg, Brian, Brown, Kimberly, Bzowej, Natalie, Caldwell, Stephen, Chami, Tawfik, Coates, Allan, Cueli, Adolfo, Davis, Mitchell, deLemos, Andrew, Desai, Archita, Dunn, Winston, Ferreira, Nelson, Fine, Michael, Firpi-Morell, Roberto, Freedland, Curtis, Freilich, Bradley, Fuchs, Michael, Galambos, Michael, Gallegos-Orozco, Juan, Galler, Greg, Ghali, Maged, Ghalib, Reem, Gill, Satinder, Gillis, Marcum, Gilroy, Richard, Gordon, Stuart, Gunn, Nadege, Halegoua-DeMarzio, Dina, Hassan, Mohamed, Hassanein, Tarek, Herring, Robert, Jr., Hong, John, Huang, Jonathan, Kabler, Heidi, Kayali, Zeid, Knapple, Whitfield, Kolli, Geetha, Kowdley, Kris, Krause, Richard, Lawitz, Eric, Lidofsky, Steven, Lim, Joseph, Lipkis, Donald, Loomba, Rohit, Mahgoub, Amar, Malespin, Miguel, Manch, Richard, Mannis, Steven, Manos, Paul, McDonald, Thomas, McKenzie, Mark, Mena, Edward, Merriman, Raphael, Moehlen, Martin William, Montgomery, Richard, Murphy, Robert, Natarajan, Yamini, Neff, Guy, Noureddin, Mazen, Ortiz-Lasanta, Grisell, Pagadala, Mangesh, Patel, Keyur, Patton, Heather, Peyton, Adam, Pimstone, Neville, Poulos, John, Pound, David, Pyrsopoulos, Nikolaos, Rafiq, Nila, Ravendhran, Natarajan, Ravinuthala, Ravi, Reddy, K. Rajendar, Reindollar, Robert, Reynolds, Justin, Rinella, Mary, Rizvi, Syed, Rockey, Don, Rodriguez-Perez, Federico, Ruane, Peter, Rubin, Raymond, Ryan, Michael, Saeian, Kia, Sanyal, Arun, Sarkar, Souvik, Scanga, Andrew, Schiff, Eugene, Schmidt, Warren, Schneider, Jeffrey, Sepe, Thomas, Shah, Dhiren, Shaikh, Obaid, Shankar, Uday, Sheikh, Aasim, Sheikh, Muhammad, Sherman, Kenneth, Shiffman, Mitchell, Siddique, Asma, Smith, Matthew, Suarez, Rosa, Talal, Andrew, Te, Helen, Tekola, Bezawit, Tetri, Brent, Thuluvath, Paul, Toro, Doris, Torres, Dawn, Trinh, Huy, Trotter, James, Vento, Angel, Vierling, John, Vuppalanchi, Raj, Waters, Michael, Weisberg, Ilan, Wieland, Amanda, Williams, Alonzo, Younes, Ziad, Adams, Leon, Harding, Damian, Hodge, Alex, Kontorinis, Nick, Strasser, Simone, Thompson, Alex, Horsmans, Yves, Steenkiste, Christophe Van, Bailey, Robert, Giard, Jeanne-Marie, Montano-Loza, Aldo, Puglia, Marco, Tsoi, Keith, Larrey, Dominique, Nguyen-Khac, Eric, Ratziu, Vlad, Spengler, Ulrich, Wiegand, Johannes, Hui, Aric Josun, Acharya, Subrat Kumar, Sarin, Shiv Kumar, Tantry, Vishwanath, Braun, Marius, Hazzan, Rawi, Lurie, Yoav, Colombo, Massimo, Fujii, Hideki, Hashimoto, Etsuko, Kato, Masaki, Ogawa, Koji, Takehara, Tetsuo, Tokushige, Katsutoshi, Garza, Laura Esthela Cisneros, Ladrón De Guevara, Alma Laura, Schultz, Michael, Janczewska, Ewa, Toro, Doris H., Jeong, Sook-Hyang, Kim, Yoon Jun, Lee, Jin-Woo, Ang, Tiing Leong, Bee, George Goh Boon, Benlloch, Salvador, Caballería, Juan, Calleja, José Luis, Rodríguez, Jose A. Carrión, Crespo, Javier, Diago, Moises, Fernandez-Rodriguez, Conrado, García-Samaniego, Javier, Ginès, Pere, Romero, Manuel, Dufour, Jean-François, Alazawi, William, Ch'ng, Chin-Lye, Forton, Daniel, Priest, Matthew, Sheridan, David, Ankoma-Sey, Victor, Balakrishnan, Maya, Bambha, Kiran, Barritt, A. Sidney, Bhandari, Bal, Brandman, Danielle, Chang, Charissa, Corey, Kathleen, Feldman, Michael, Gholam, Pierre, Goff, John, Marzio, Dina Halegoua-De, Harrison, Stephen, Hellstern, Paul, Jr., Herring, Robert, Iyer, Rajalakshmi, Jakiche, Antoine, Kohli, Anita, Krok, Karen, Kugelmas, Marcelo, Kumar, Sonal, Lai, Michelle, Mahmoud, Mitchell, Mantry, Parvez, Marsano, Luis, Nguyen, Tuan, Park, James, Patton, Heather M., Pockros, Paul, Reddy, Rajender, Rodriguez, Miguel, Sarles, Harry, Satapathy, Sanjaya, Sedghi, Shahriar, Shah, Nikunj, Sheikh, Muhammad Yasin, Sigal, Samuel, Stanca, Carmen, Steinbook, Michael, Szabo, Gyongyi, Terrault, Norah, Tong, Myron, Victor, David, Zervos, Xaralambos, Harrison, Stephen A., Wong, Vincent Wai-Sun, Caldwell, Stephen H., Shiffman, Mitchell L., Camargo, Marianne, Li, Georgia, Kersey, Kathryn, Jia, Catherine, Zhu, Yanni, Djedjos, C. Stephen, Subramanian, G. Mani, Myers, Robert P., Anstee, Quentin M., Romero-Gomez, Manuel, Goodman, Zachary, Lawitz, Eric J., and Younossi, Zobair

Published
2020
Full Text
View/download PDF

20. Researchers call for more flexible editorial conduct rather than abruptly adopting only the new MASLD nomenclature

Author

Lonardo, Amedeo, primary, Bril, Fernando, additional, Caldwell, Stephen H., additional, Eslam, Mohammed, additional, Fan, Jian-Gao, additional, Gish, Robert G., additional, Gronbaek, Henning, additional, Sanal, Madhusudana Girija, additional, Stefan, Norbert, additional, Suzuki, Ayako, additional, Targher, Giovanni, additional, Tilg, Herbert, additional, Yu, Ming-Lung, additional, Zheng, Ming-Hua, additional, and George, Jacob, additional

Published
2024
Full Text
View/download PDF

39. Contributors

Author

Afdhal, Nezam H., primary, Allen, Alina M., additional, Ambade, Aditya, additional, Anstee, Quentin M., additional, Asrani, Sumeet K., additional, Assis, Davis N., additional, Bajaj, Jasmohan Singh, additional, Balistreri, William F., additional, Banales, Jesus M., additional, Bendall, Richard, additional, Benson, Ariel, additional, Bertoletti, Antonio, additional, Bezerra, Jorge A., additional, Biggins, Scott W., additional, Bonkovsky, Herbert L., additional, Bowlus, Christopher, additional, Boyer, Thomas D., additional, Brenner, David A., additional, Brunt, Elizabeth M., additional, Caldwell, Stephen H., additional, Chalasani, Naga, additional, Cogley, Jonathan R., additional, Colombo, Massimo, additional, Cong, Min, additional, Crabb, David W., additional, Crawford, James M., additional, Dalton, Harry R., additional, Dasarathy, Srinivasan, additional, Day, Christopher P., additional, DeLeve, Laurie D., additional, Devaraj, Kalpana M., additional, Devarbhavi, Harshad, additional, Diehl, Anna Mae, additional, Drenth, Joost P.H., additional, Ramahi, Razan El, additional, Elbaz, Tamer Mahmoud, additional, Elkrief, Laure, additional, Esmat, Gamal, additional, Everson, Gregory Thomas, additional, Factor, Phillip, additional, Fallon, Michael B., additional, Feng, Sandy, additional, Forbes, Stuart, additional, Gao, Bin, additional, Garcia-Tsao, Guadalupe, additional, Ghufran, Aiman, additional, Gillevet, Patrick Martin, additional, Glenn, Jeffrey S., additional, Goldberg, David, additional, Gordon, Stuart C., additional, Gores, Gregory J., additional, Habib, Shahid, additional, Harrison, Stephen A., additional, Heller, Theo, additional, Helmke, Steve M., additional, Holtzman, Deborah, additional, Intagliata, Nicolas M., additional, Izopet, Jacques, additional, Jafri, Syed-Mohammed, additional, Janssen, Harry L.A., additional, Jia, Jidong, additional, Kalb, Bobby T., additional, Kamath, Patrick S., additional, Karpen, Saul J., additional, Karvellas, Constantine J., additional, Kisseleva, Tatiana, additional, Klotz, Stephen A., additional, Koh, Christopher, additional, Kohli, Rohit, additional, Konerman, Monica A., additional, Kottilil, Shyamasundaran, additional, Kulik, Laura, additional, Kuruvilla, Asha C., additional, Lammert, Frank, additional, Lazaridis, Konstantinos N., additional, Lencioni, Riccardo, additional, Levy, Cynthia, additional, Li, Hongxia, additional, Liangpunsakul, Suthat, additional, Lohse, Ansgar W., additional, Lok, Anna S., additional, Loudianos, Georgios, additional, Lucey, Michael R., additional, Machado, Mariana Verdelho, additional, Martin, Diego R., additional, Meissner, Eric G., additional, Miller, Frank H., additional, Muir, Andrew J., additional, Nevah, Moises I., additional, O'Neill, Erin K., additional, Oren, Ran, additional, Patidar, Kavish R., additional, Pence, Mark M., additional, Perlmutter, David, additional, Pietrangelo, Antonello, additional, Prenner, Stacey, additional, Puri, Puneet, additional, Qin, Lihui, additional, Razumilava, Nataliya, additional, Reijnders, Jurrien, additional, Roberts, Eve A., additional, Roberts, Lewis R., additional, Roy-Chowdhury, Jayanta, additional, Roy-Chowdhury, Namita, additional, Russo, Mark, additional, Saab, Sammy, additional, Saha, Banishree, additional, Sangiovanni, Angelo, additional, Saxena, Varun, additional, Schwarz, Kathleen B., additional, Sclair, Seth N., additional, Seijo, Susana, additional, Setchell, Kenneth D.R., additional, Shah, Vijay H., additional, Shaikh, Obaid S., additional, Sherman, Kenneth E., additional, Simonetto, Douglas A., additional, Singal, Ashwani K., additional, Sonneveld, Milan, additional, Squires, James E., additional, Sterling, Richard K., additional, Stratton, Amy N., additional, Stravitz, R. Todd, additional, Strom, Stephen, additional, Szabo, Gyongyi, additional, Talwalkar, Jayant A., additional, Tang, Lydia, additional, Tapper, Elliot B., additional, Terrault, Norah A., additional, Torres, Dawn M., additional, Vagefi, Parsia A., additional, Valla, Dominique C., additional, Vander Kooi, Douglas C., additional, Ward, John W., additional, Wedd, Joel P., additional, Weiler-Normann, Christina, additional, Wong, Florence, additional, Yang, Ju Dong, additional, Zakhari, Samir, additional, Zangeneh, Tirdad T., additional, Zayed, Naglaa, additional, and Zoulim, Fabien, additional

Published
2018
Full Text
View/download PDF

43. Effects of n-3 fish oil on metabolic and histological parameters in NASH: A double-blind, randomized, placebo-controlled trial

Author

Argo, Curtis K., Patrie, James T., Lackner, Carolin, Henry, Thomas D., de Lange, Eduard E., Weltman, Arthur L., Shah, Neeral L., Al-Osaimi, Abdullah M., Pramoonjago, Patcharin, Jayakumar, Saumya, Binder, Lukas P., Simmons-Egolf, Winsor D., Burks, Sandra G., Bao, Yongde, Taylor, Ann Gill, Rodriguez, Jessica, and Caldwell, Stephen H.

Published
2015
Full Text
View/download PDF

46. Genetic inhibition of hepatic acetyl-CoA carboxylase activity increases liver fat and alters global protein acetylation

Author

Chow, Jenny D.Y., Lawrence, Robert T., Healy, Marin E., Dominy, John E., Liao, Jason A., Breen, David S., Byrne, Frances L., Kenwood, Brandon M., Lackner, Carolin, Okutsu, Saeko, Mas, Valeria R., Caldwell, Stephen H., Tomsig, Jose L., Cooney, Gregory J., Puigserver, Pere B., Turner, Nigel, James, David E., Villén, Judit, and Hoehn, Kyle L.

Published
2014
Full Text
View/download PDF

48. Contributors for Volume 1

Author

Abbas, Zaigham, Abdullah, Khalid, Acharya, Subrat Kumar, Aghayeva, Gulnara, Ahmad, Jawad, Akbar, Sheikh Mohammad Fazle, Arora, Anil, Asp, Patrik, Bansal, Meena B., Bedewy, Essam, Bernardi, Mauro, Bernstein, David, Boregowda, Umesha, Caldwell, Stephen H., Calmet, Fernando, Carlini, Lauren E., Crawford, James M., Dhiman, Radha K., Dhiman, Siddhant, Dutta, Usha, Gallagher, Julie, Gish, Robert G., Grewal, Priya, Guha, Chandan, Gupta, Pankaj, Gutierrez, Julio A., Jothimani, Dinesh, Kar, Premashis, Karna, Rahul, Khanna, Rohit, Koneru, Gopala, Kothadia, Jiten P., Latt, Nyan L., Levy, Cynthia, Mamun-Al-Mahtab, Maliakkal, Benedict J., Manjunath, Srividya, Mann, Rupinder, Martin, Paul, Miller, Jennifer B., Omiwade, Oluwaposi, Ormeci, Necati, Prevallet, Alex, Rattan, Puru, Rizzetto, Mario, Roy, Akash, Roy-Chowdhury, Jayanta, Roy-Chowdhury, Namita, Satiya, Jinendra, Shah, Vijay H., Sharma, Praveen, Sheflin-Findling, Shari, Siddiqui, Mohammad, Snyder, Heather, Syed, Taseen, Trivella, Juan, Tseng, Michael, Turcanu, Adela, Udompap, Prowpanga, Umukoro, Emuejevuoke, Wakil, Ali, Wentworth, Brian J., Wong, Robert J., Yadav, Amit, and Zaccherini, Giacomo

Published
2025
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results